



Announcement Summary

Entity name

NANOVEU LIMITED

Announcement Type

New announcement

Date of this announcement

Monday June 8, 2020

The Proposed issue is:

☒ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +Security Code	+Security Description	Maximum Number of +securities to be issued
NVUAH	OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	3,250,000

Proposed +issue date

Tuesday June 9, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

NANOVEU LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

97624421085

1.3 ASX issuer code

NVU

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

Monday June 8, 2020

1.6 The Proposed issue is:

☒ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

☒ No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

☒ Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

☒ No

Details of +securities proposed to be issued

ASX +Security Code and Description

NVUAH : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES

Maximum Number of +securities proposed to be issued

3,250,000

Purpose of the issue

Part of the remuneration of a consultant

Offer price details for retail security holders

In what currency is the cash consideration being paid?

What is the issue price per +security?

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ No



Oversubscription & Scale back details

May a scale back be applied to this event?

☒ No

If some of the issued +securities do not rank equally

Is the actual date from which the +securities will rank equally (non-ranking end date) known?

☒ No

Provide the estimated non-ranking end period

3,250,000 performance options have an exercise price of \$0.20, expiry date of 31 December 2023 (Options) and are exercisable upon vesting conditions being achieved.

Please state the extent to which the +securities do not rank equally:

- In relation to the next dividend, distribution or interest payment; or
- For any other reason

The securities will rank equally with ordinary shares if vesting conditions are achieved and the options are exercised. Until this time, they do not rank equally with other securities.

Part 7C - Timetable

7C.1 Proposed +issue date

Tuesday June 9, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

3,250,000

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No

7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?

☒ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

☒ No



7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

☒ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

☒ No

7E.2 Is the proposed issue to be underwritten?

☒ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

n/a

Part 7F - Further Information

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

☒ No



7F.2 Any other information the entity wishes to provide about the proposed issue

3,250,000 performance options issued to Digital 360 Inc (D360) which have an exercise price of \$0.20, expiry date of 31 December 2023 (Options) and are exercisable upon the following vesting conditions being achieved:

(i) (Tranche 1): 500,000 Options shall vest upon Nanoveu generating US\$2,500,000 in revenue from sales of Nanoveu's antiviral protectors for smart phones (Products) to customers introduced to Nanoveu by D360 by the later of:

(A) 31 December 2020; and

(B) the date which is 7 months from the date on which Nanoveu announces that Products are available for commercial sale;

(ii) (Tranche 2): 750,000 Options shall vest upon Nanoveu generating US\$5,000,000 in revenue from sales of Nanoveu's antiviral protectors for smart phones (Products) to customers introduced to Nanoveu by D360 by the later of:

(A) 31 December 2020; and

(B) the date which is 7 months from the date on which Nanoveu announces that Products are available for commercial sale;

(iii) (Tranche 3): 1,000,000 Options shall vest upon Nanoveu generating US\$20,000,000 in revenue from sales of antiviral protectors for smart phones (Products) to customers introduced to Nanoveu by D360 by the later of:

(A) 31 December 2021; and

(B) the date which is 19 months from the date on which Nanoveu announces that Products are available for commercial sale; and

(iv) (Tranche 4): 1,000,000 Options shall vest upon Nanoveu generating US\$50,000,000 in revenue from sales of antiviral protectors for smart phones (Products) to customers introduced to Nanoveu by D360 by the later of:

(A) 31 December 2022; or

(B) the date which is 31 months from date on which Nanoveu announces that Products are available for commercial sale.

An Option will only vest subject to Nanoveu achieving the vesting conditions defined above after the Nanoveu's auditor verifies that, based on Nanoveu's accounts and records, the relevant vesting condition has been satisfied.

Nanoveu must instruct its auditor to complete the necessary verification work within 30 days following the relevant vesting date.